Financial Performance - Total revenue for the year ended December 31, 2023, was RMB 189,384,000, an increase of 15.1% from RMB 164,522,000 in 2022[5] - Gross profit for the same period was RMB 71,493,000, representing a gross margin of 37.7%, compared to RMB 66,783,000 in 2022[5] - The company reported a net loss of RMB 37,779,000 for the year, which is a 86.3% increase from the net loss of RMB 20,247,000 in 2022[5] - The company reported a loss before tax of RMB 35,010 thousand for the year, compared to a loss of RMB 22,101 thousand in 2022[24] - The company recorded a total annual loss attributable to equity holders of approximately RMB 32.5 million in 2023, compared to RMB 15.9 million in 2022[45] - The company reported a basic loss per share of RMB 7.77 for 2023, compared to RMB 3.81 for 2022, indicating a significant increase in losses per share[39] - The group reported a pre-tax loss of RMB 35,010,000 for 2023, compared to a loss of RMB 22,101,000 in 2022, representing a year-over-year increase of 58.5% in losses[33] Revenue Breakdown - Revenue from medical beauty services reached RMB 174,910 thousand, up 15.3% from RMB 151,661 thousand in the previous year[25] - Revenue from medical beauty equipment products increased to RMB 14,474 thousand, a rise of 12.8% compared to RMB 12,834 thousand in 2022[25] - Revenue from minimally invasive beauty services and skin beauty services was approximately RMB 830 million and RMB 833 million, representing increases of 12.3% and 30.8% compared to 2022[72] - The revenue from cosmetic surgery services in 2023 was approximately RMB 69 million, a decrease of 33.3% from RMB 104 million in 2022, primarily due to technological advancements and changing consumer preferences[72] Expenses and Costs - Research and development expenses decreased to RMB 1,602,000 from RMB 2,000,000, indicating a focus on cost management[5] - The company recognized impairment losses of RMB 11,970 thousand, compared to RMB 6,378 thousand in the previous year[24] - The total sales cost for 2023 was approximately RMB 1,179 million, an increase of about 20.6% from RMB 977 million in 2022[73] - Selling and distribution expenses for 2023 were approximately RMB 523 million, up about 6.1% from RMB 493 million in 2022, mainly due to increased live-streaming promotion costs[83] - Administrative expenses for 2023 were approximately RMB 401 million, an increase of about RMB 42 million from RMB 359 million in 2022[84] Assets and Liabilities - Total assets as of December 31, 2023, amounted to RMB 273,599 thousand, down from RMB 302,651 thousand in 2022[24] - Total liabilities increased to RMB 141,009 thousand, compared to RMB 136,774 thousand in the previous year[24] - Total current liabilities increased to RMB 92,159,000 from RMB 76,413,000, indicating a rise in short-term financial obligations[6] - The company's equity attributable to owners of the parent decreased to RMB 138,115,000 from RMB 166,080,000, reflecting a decline in shareholder value[7] - The total debt of the group as of December 31, 2023, was approximately RMB 141.0 million, compared to RMB 136.8 million as of December 31, 2022, resulting in a debt-to-equity ratio of approximately 106.3%, up from 82.5% in the previous year[96] Cash Flow and Liquidity - Cash and bank balances decreased significantly to RMB 39,790,000 from RMB 78,779,000, reflecting liquidity challenges[6] - The group has established a cautious treasury policy, continuously assessing the financial status of clients to mitigate credit risk and closely monitoring liquidity to meet funding needs[99] Strategic Plans and Market Position - The company plans to focus on expanding its medical beauty services and product offerings in the coming year[24] - The company aims to increase market share for its medical beauty equipment products by enhancing sales networks and investing in new product development[57] - The company plans to allocate approximately 40% of the net proceeds from the share offering for the registration of medical beauty devices with the National Medical Products Administration[59] - The company plans to raise up to approximately HKD 20.8 million through a rights issue, with an estimated net proceeds of about HKD 19.4 million[126] Corporate Governance and Compliance - The audit committee has reviewed and approved the consolidated financial statements for the year ending December 31, 2023, ensuring compliance with applicable accounting standards and regulations[144] - The company has adopted the corporate governance code as per the listing rules, emphasizing transparency, accountability, and independence[133][134] - The company has confirmed compliance with the standards set forth in the code of conduct for securities trading by all directors during the year[132] Employee and Operational Metrics - The total employee cost was approximately RMB 68.8 million, an increase of RMB 5.0 million from RMB 63.8 million in 2022, accounting for 36.3% of total revenue in 2023 (2022: 38.8%)[115] - The company had a total of 335 employees in China as of December 31, 2023, up from 322 employees in 2022[114] Market Trends and Industry Outlook - The medical beauty industry is expected to experience strong growth, supported by government policies emphasizing the development of anti-aging technologies and services[128] - The company will focus on developing non-surgical medical beauty services and increase investment in technology and research for personalized anti-aging services and products[128]
瑞丽医美(02135) - 2023 - 年度业绩